Boston Scientific Corporation (BSX) DCF Valuation

Boston Scientific Corporation (BSX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Boston Scientific Corporation (BSX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Boston Scientific Corporation's (BSX) financial outlook with expertise! This (BSX) DCF Calculator comes equipped with pre-filled financial data and offers complete flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 10,735.0 9,913.0 11,888.0 12,682.0 14,240.0 15,351.8 16,550.4 17,842.6 19,235.7 20,737.5
Revenue Growth, % 0 -7.66 19.92 6.68 12.29 7.81 7.81 7.81 7.81 7.81
EBITDA 2,210.0 1,511.0 2,518.0 2,741.0 3,453.0 3,158.6 3,405.2 3,671.0 3,957.6 4,266.6
EBITDA, % 20.59 15.24 21.18 21.61 24.25 20.57 20.57 20.57 20.57 20.57
Depreciation 1,010.0 1,122.0 1,093.0 1,136.0 1,196.0 1,451.6 1,564.9 1,687.1 1,818.8 1,960.8
Depreciation, % 9.41 11.32 9.19 8.96 8.4 9.46 9.46 9.46 9.46 9.46
EBIT 1,200.0 389.0 1,425.0 1,605.0 2,257.0 1,707.0 1,840.2 1,983.9 2,138.8 2,305.8
EBIT, % 11.18 3.92 11.99 12.66 15.85 11.12 11.12 11.12 11.12 11.12
Total Cash 217.0 1,734.0 1,925.0 928.0 865.0 1,507.5 1,625.2 1,752.1 1,888.9 2,036.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 1,828.0 1,531.0 1,778.0 1,970.0 2,228.0
Account Receivables, % 17.03 15.44 14.96 15.53 15.65
Inventories 1,579.0 1,351.0 1,610.0 1,867.0 2,484.0 2,273.5 2,451.0 2,642.3 2,848.6 3,071.1
Inventories, % 14.71 13.63 13.54 14.72 17.44 14.81 14.81 14.81 14.81 14.81
Accounts Payable 542.0 513.0 794.0 862.0 942.0 930.8 1,003.5 1,081.8 1,166.3 1,257.3
Accounts Payable, % 5.05 5.18 6.68 6.8 6.62 6.06 6.06 6.06 6.06 6.06
Capital Expenditure -461.0 -376.0 -554.0 -612.0 -800.0 -712.1 -767.6 -827.6 -892.2 -961.9
Capital Expenditure, % -4.29 -3.79 -4.66 -4.83 -5.62 -4.64 -4.64 -4.64 -4.64 -4.64
Tax Rate, % 19.75 19.75 19.75 19.75 19.75 19.75 19.75 19.75 19.75 19.75
EBITAT 8,209.6 394.6 1,378.6 981.8 1,811.3 1,495.9 1,612.7 1,738.6 1,874.3 2,020.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 5,893.6 1,636.6 1,692.6 1,124.8 1,412.3 2,249.2 2,116.7 2,281.9 2,460.1 2,652.2
WACC, % 7.96 7.96 7.95 7.85 7.9 7.92 7.92 7.92 7.92 7.92
PV UFCF
SUM PV UFCF 9,341.4
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) 2,758
Terminal Value 70,293
Present Terminal Value 48,009
Enterprise Value 57,351
Net Debt 8,627
Equity Value 48,724
Diluted Shares Outstanding, MM 1,464
Equity Value Per Share 33.29

What You Will Receive

  • Comprehensive Financial Model: Boston Scientific’s actual data facilitates accurate DCF valuation.
  • Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential variables.
  • Real-Time Calculations: Automatic updates provide immediate insights as you implement changes.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Adjustable and Repeatable: Designed for adaptability, allowing for consistent use in detailed forecasts.

Key Features

  • 🔍 Real-Life BSX Financials: Pre-filled historical and projected data for Boston Scientific Corporation (BSX).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Boston Scientific’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Boston Scientific’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Boston Scientific Corporation’s (BSX) data.
  • Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Boston Scientific Corporation’s (BSX) intrinsic value.
  • Step 5: Utilize the outputs to make informed investment decisions or create detailed reports.

Why Choose This Calculator?

  • Accurate Data: Real Boston Scientific Corporation (BSX) financials ensure reliable valuation results.
  • Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
  • Time-Saving: Pre-built calculations eliminate the need to start from scratch.
  • Professional-Grade Tool: Designed for investors, analysts, and consultants.
  • User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.

Who Should Use This Product?

  • Investors: Accurately estimate Boston Scientific Corporation’s (BSX) fair value before making investment decisions.
  • CFOs: Leverage a professional-grade DCF model for financial reporting and analysis related to Boston Scientific Corporation (BSX).
  • Consultants: Quickly adapt the template for valuation reports for clients focused on Boston Scientific Corporation (BSX).
  • Entrepreneurs: Gain insights into financial modeling used by leading companies like Boston Scientific Corporation (BSX).
  • Educators: Use it as a teaching tool to demonstrate valuation methodologies relevant to Boston Scientific Corporation (BSX).

What the Template Contains

  • Preloaded BSX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.